Last reviewed · How we verify

NCT05854238

The Study for Evaluate of Safety and Efficacy of Vein of Marshall RF Ablation

Terminated NA Last updated 15 April 2025
What this trial tests

NA trial testing TIRA-VoM in Persistent Atrial Fibrillation in 4 participants. Terminated before completion.

Timeline
3 August 2023
Primary endpoint
4 April 2024
7 April 2025

Quick facts

Lead sponsorTau-MEDICAL Co., Ltd.
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposedevice feasibility
Enrollment4
Start date3 August 2023
Primary completion4 April 2024
Estimated completion7 April 2025
Sites2 locations across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Tau-MEDICAL Co., Ltd. — full company profile →

Who can join

20 and older, any sex, with Persistent Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to evaluate the initial safety and effectiveness of an investigational medical device. Electrode catheter ablation of the Marshall vein is performed using TIRA, a clinical trial medical device for patients with persistent atrial fibrillation,

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Persistent Atrial Fibrillation

Currently open trials in the same condition.

Other Tau-MEDICAL Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05854238.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing